[go: up one dir, main page]

WO2025162289A3 - Crystalline form of pde4b inhibitor and pharmaceutical use thereof - Google Patents

Crystalline form of pde4b inhibitor and pharmaceutical use thereof

Info

Publication number
WO2025162289A3
WO2025162289A3 PCT/CN2025/074794 CN2025074794W WO2025162289A3 WO 2025162289 A3 WO2025162289 A3 WO 2025162289A3 CN 2025074794 W CN2025074794 W CN 2025074794W WO 2025162289 A3 WO2025162289 A3 WO 2025162289A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
pharmaceutical use
pde4b inhibitor
pde4b
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/074794
Other languages
French (fr)
Chinese (zh)
Other versions
WO2025162289A2 (en
Inventor
宫正
陈清平
马金翼
蒋琦
范江
窦赢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisco Pharmaceutical Co Ltd
Original Assignee
Tibet Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibet Haisco Pharmaceutical Co Ltd filed Critical Tibet Haisco Pharmaceutical Co Ltd
Publication of WO2025162289A2 publication Critical patent/WO2025162289A2/en
Publication of WO2025162289A3 publication Critical patent/WO2025162289A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a PDE4B inhibitor compound as shown in formula (I) or a crystalline form of a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition thereof, and a pharmaceutical use thereof.
PCT/CN2025/074794 2024-02-04 2025-01-24 Crystalline form of pde4b inhibitor and pharmaceutical use thereof Pending WO2025162289A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202410158314.8 2024-02-04
CN202410158314 2024-02-04

Publications (2)

Publication Number Publication Date
WO2025162289A2 WO2025162289A2 (en) 2025-08-07
WO2025162289A3 true WO2025162289A3 (en) 2025-09-18

Family

ID=96589524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/074794 Pending WO2025162289A2 (en) 2024-02-04 2025-01-24 Crystalline form of pde4b inhibitor and pharmaceutical use thereof

Country Status (1)

Country Link
WO (1) WO2025162289A2 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163706A (en) * 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 Dihydrothienopyrimidines for the treatment of inflammatory diseases
CN101426505A (en) * 2006-04-19 2009-05-06 贝林格尔.英格海姆国际有限公司 Dihydrothienopyrimidine for treating inflammatory disorders
CN101827853A (en) * 2007-10-19 2010-09-08 贝林格尔.英格海姆国际有限公司 Heterocycle-substituted piperazino-dihydrothienopyrimidines
CN101903394A (en) * 2007-10-18 2010-12-01 贝林格尔.英格海姆国际有限公司 Preparation of dihydrothieno [3,2-D ] pyrimidines and intermediates used therein
US20110028441A1 (en) * 2007-10-19 2011-02-03 Boehringer Ingelheim International Gmbh Novel phenyl-substituted piperazino-dihydrothienopyrimidines
US20110046096A1 (en) * 2007-10-19 2011-02-24 Boehringer Ingelheim International Gmbh Novel piperazino-dihydrothienopyrimidine derivatives
US20120028932A1 (en) * 2009-02-27 2012-02-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4 inhibitors and nsaids
US20120035143A1 (en) * 2009-02-27 2012-02-09 Boehringer Ingelheim International Gmbh Drug combinations containing pde4 inhibitors and nsaids
US20130225609A1 (en) * 2010-04-08 2013-08-29 Boehringer Ingelheim International Gmbh Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists
WO2023232135A1 (en) * 2022-06-02 2023-12-07 西藏海思科制药有限公司 Pde4b inhibitor and use thereof
CN117247395A (en) * 2022-06-16 2023-12-19 武汉人福创新药物研发中心有限公司 PDE4B inhibitors
WO2024032673A1 (en) * 2022-08-09 2024-02-15 西藏海思科制药有限公司 Pde4b inhibitor and use thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163706A (en) * 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 Dihydrothienopyrimidines for the treatment of inflammatory diseases
CN101426505A (en) * 2006-04-19 2009-05-06 贝林格尔.英格海姆国际有限公司 Dihydrothienopyrimidine for treating inflammatory disorders
CN101903394A (en) * 2007-10-18 2010-12-01 贝林格尔.英格海姆国际有限公司 Preparation of dihydrothieno [3,2-D ] pyrimidines and intermediates used therein
CN101827853A (en) * 2007-10-19 2010-09-08 贝林格尔.英格海姆国际有限公司 Heterocycle-substituted piperazino-dihydrothienopyrimidines
US20110028441A1 (en) * 2007-10-19 2011-02-03 Boehringer Ingelheim International Gmbh Novel phenyl-substituted piperazino-dihydrothienopyrimidines
US20110046096A1 (en) * 2007-10-19 2011-02-24 Boehringer Ingelheim International Gmbh Novel piperazino-dihydrothienopyrimidine derivatives
US20120028932A1 (en) * 2009-02-27 2012-02-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4 inhibitors and nsaids
US20120035143A1 (en) * 2009-02-27 2012-02-09 Boehringer Ingelheim International Gmbh Drug combinations containing pde4 inhibitors and nsaids
US20130225609A1 (en) * 2010-04-08 2013-08-29 Boehringer Ingelheim International Gmbh Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists
WO2023232135A1 (en) * 2022-06-02 2023-12-07 西藏海思科制药有限公司 Pde4b inhibitor and use thereof
CN117247395A (en) * 2022-06-16 2023-12-19 武汉人福创新药物研发中心有限公司 PDE4B inhibitors
WO2024032673A1 (en) * 2022-08-09 2024-02-15 西藏海思科制药有限公司 Pde4b inhibitor and use thereof

Also Published As

Publication number Publication date
WO2025162289A2 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
CA2414018A1 (en) 2-aminocarbonyl-9h-purine derivatives
CA2320233A1 (en) Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
CA2463976A1 (en) N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
NO20063231L (en) Pyrido [2,3-D] pyrimidine-2,4-diamines as PDE 2 inhibitors
WO2002010154A3 (en) Substituted heterocyclic amides
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2007072158A3 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20040881L (en) Oral antidiabetic agents.
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
CA2469592A1 (en) Hiv integrase inhibitors
MX2023004033A (en) Spiro derivatives of alpha-d-galactopyranosides.
CA2406266A1 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
AU2024252725A1 (en) Kras modulating compounds
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
CA2494321A1 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
AU2003263498A1 (en) Pyrazole derivatives
WO2024073106A8 (en) Compounds and compositions useful as inhibitors of iaps
MX2022006104A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor.
WO2003054001A3 (en) Method for preparing echinocandin derivatives and their compositions
WO2024086789A3 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
AU2001282871A1 (en) Antithrombotic agents
CA3155875A1 (en) Sulfo-substituted biaryl compounds or salts thereof and preparation method and use thereof
WO2003086319A3 (en) Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
WO2025162289A3 (en) Crystalline form of pde4b inhibitor and pharmaceutical use thereof
NO983444D0 (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25747857

Country of ref document: EP

Kind code of ref document: A2